Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post- acute cOroNary sYndromes (SYMPHONY) trial

American Heart Journal

Volumn 138, Issue 2 I, 1999, Pages 210-218

  Newby, L K ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATINE KINASE; FIBRINOGEN RECEPTOR ANTAGONIST; SIBRAFIBAN; TICLOPIDINE;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0032811508     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70104-3     Document Type: Article

References (36)

1. American Heart Association. 1998 heart and stroke statistical update. Dallas (TX): American Heart Association; 1997. p. 3.
2. Graves E, Owings M. 1995 summary: national hospital discharge survey. Hyattesville (MD): Centers for Disease Control, National Center of Health Statistics; 1997.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
4. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
5. The PARAGON Investigators. International, randomized, controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina. Circulation 1998;97:2386-95.
6. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
7. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
8. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
10. Hennekens CH, Eberlain K, for the Physicians' Health Study Research Group. A randomized trial of aspirin and β-carotene among US physicians. Prev Med 1985;14:165-8.
11. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 193;35:219-26.
12. Weiss HJ, Aledort LM. Impaired platelet-connective tissue reaction in man after aspirin ingestion. Lancet 1967;2:495-7.
13. O'Brien JR. Effects of salicylates on human platelets. Lancet 1968;1:779-83.
14. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot trial including 180 post-stroke patients. Thromb Res 1993;71:397-403.
15. Farrell TP, Hayes KA, Tracy PB, Sobel DJ. Unexpected, discordant effect of aspirin on platelet reactivity [abstract]. J Am Coll Cardiol 1998;31(suppl A):352A.
16. Mueller MR, Salat A, Stangl P, et al. Variable response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-7.
17. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995;11:221-7.
18. Van Belle E, Lablanche J, Bauters C, Renaud N, McFadden E, Bertrand M. Coronary angioscopic findings in the infarct-related vessel with 1 month of acute myocardial infarction: natural history and the effect of thrombolysis. Circulation 1998;97:26-33.
19. Merlini P, Bauer K, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-8.
20. Ginsberg MH, Du X, O'Toole TE, Loftus JC. Platelet integrins. Thromb Haemost 1995;74:352-9.
21. Lefkovits J, Plow E, Topol E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
22. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary blood flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation 1997;95:1755-9.
23. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
24. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
25. The CAPTURE Investigators. Randomized placebo-controlled trial of the abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-35.
26. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet 1998; 352:87-92.
27. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
28. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI 8) pilot study. J Am Coll Cardiol 1993;22:381-9.
29. Ohman EM, Kleiman NS, Gacioch G, et al for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-54.
30. Ohman EM, Lincoff AM, Bode C, et al. Enhanced early reperfusion at 60 minutes with low-dose reteplase combined with full-dose abciximab in acute myocardial infarction: preliminary results from the GUSTO-4 pilot (SPEED) dose-ranging trial [abstract]. Circulation 1998;98:I-540.
31. Antman EM, Giugliano RP, McCabe CH, et al. Abciximab (ReoPro) potentiates thrombolysis in ST elevation myocardial infarction: results of TIMI 14 trial [abstract]. J Am Coll Cardiol 1998;31:191A.
32. Modi N, Lin Y, Reynolds T, Shaheen A, Christian B. Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles. J Cardiovasc Pharmacol 1998;32:397-405.
33. Cannon CP, McCabe C, Borzak S, et al. Randomized trial of an oral platelet glyocprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation 1998;97:340-9.
34. Theroux P, Kouz S, Roy L, et al. Platelet membrane glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996;94:899-905.
35. The IMPACT-II Investigators. Randomized placebo-controlled trial of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-8.
36. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1998;74:800-2.